130 related articles for article (PubMed ID: 21455983)
1. Immunotherapeutic efficacy of Mycobacterium indicus pranii in eliciting anti-tumor T cell responses: critical roles of IFNγ.
Rakshit S; Ponnusamy M; Papanna S; Saha B; Ahmed A; Nandi D
Int J Cancer; 2012 Feb; 130(4):865-75. PubMed ID: 21455983
[TBL] [Abstract][Full Text] [Related]
2. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
3. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
4. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
5. Activation of anti-tumor immune response and reduction of regulatory T cells with Mycobacterium indicus pranii (MIP) therapy in tumor bearing mice.
Ahmad F; Mani J; Kumar P; Haridas S; Upadhyay P; Bhaskar S
PLoS One; 2011; 6(9):e25424. PubMed ID: 21984926
[TBL] [Abstract][Full Text] [Related]
6. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes.
Margalit M; Shibolet O; Klein A; Elinav E; Alper R; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2005 Jun; 115(3):443-9. PubMed ID: 15688366
[TBL] [Abstract][Full Text] [Related]
7. Transfer of IFNgamma-depleted CD4(+) T cells together with CD8(+) T cells leads to rejection of murine kidney sarcoma in mice.
Klugewitz K; Scheffold A; Radbruch A; Hamann A
Int J Cancer; 2000 Sep; 87(5):673-9. PubMed ID: 10925361
[TBL] [Abstract][Full Text] [Related]
8. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Sep; 7(18):1527-35. PubMed ID: 11021590
[TBL] [Abstract][Full Text] [Related]
9. Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model.
Gupta A; Ahmad FJ; Ahmad F; Gupta UD; Natarajan M; Katoch VM; Bhaskar S
Vaccine; 2012 Sep; 30(43):6198-209. PubMed ID: 22871353
[TBL] [Abstract][Full Text] [Related]
10. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
11. Native anti-tumor responses elicited by immunization with a low dose of unmodified live tumor cells.
Wu S; Wang SQ; Zhang J; Tan XY; Liu JN
Int J Oncol; 2006 Mar; 28(3):731-6. PubMed ID: 16465379
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
[TBL] [Abstract][Full Text] [Related]
13. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
14. Cell wall fraction of Mycobacterium indicus pranii shows potential Th1 adjuvant activity.
Saqib M; Khatri R; Singh B; Gupta A; Bhaskar S
Int Immunopharmacol; 2019 May; 70():408-416. PubMed ID: 30856391
[TBL] [Abstract][Full Text] [Related]
15. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
16. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
17. Type 1 interferon mediated signaling is indispensable for eliciting anti-tumor responses by
Roy G; Chakraborty A; Swami B; Pal L; Ahuja C; Basak S; Bhaskar S
Front Immunol; 2023; 14():1104711. PubMed ID: 37122749
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD3 single-chain Fv/interleukin-18 fusion DNA induces anti-mycobacterial resistance via efficient interferon-gamma production in BALB/c mice infected with Mycobacterium avium.
Kim SH; Cho D; Kim TS
Vaccine; 2006 Apr; 24(16):3365-73. PubMed ID: 16481075
[TBL] [Abstract][Full Text] [Related]
19. IL-15-induced CD8+CD122+ T cells increase antibacterial and anti-tumor immune responses: implications for immune function in aged mice.
Motegi A; Kinoshita M; Inatsu A; Habu Y; Saitoh D; Seki S
J Leukoc Biol; 2008 Oct; 84(4):1047-56. PubMed ID: 18653461
[TBL] [Abstract][Full Text] [Related]
20. IL-10 elicits IFNγ-dependent tumor immune surveillance.
Mumm JB; Emmerich J; Zhang X; Chan I; Wu L; Mauze S; Blaisdell S; Basham B; Dai J; Grein J; Sheppard C; Hong K; Cutler C; Turner S; LaFace D; Kleinschek M; Judo M; Ayanoglu G; Langowski J; Gu D; Paporello B; Murphy E; Sriram V; Naravula S; Desai B; Medicherla S; Seghezzi W; McClanahan T; Cannon-Carlson S; Beebe AM; Oft M
Cancer Cell; 2011 Dec; 20(6):781-96. PubMed ID: 22172723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
